M.D., Adult Medical Oncologist, University of Chicago
As an adult medical oncologist, Daniel Catenacci, MD, specializes in the treatment of gastrointestinal malignancies. He provides skilled care for a range of gastrointestinal cancers, including gastric (stomach) cancer, esophageal cancer and gastroesophageal junction cancer. Dr. Catenacci works with a multidisciplinary team of surgical oncologists, radiation oncologists, and medical oncologists to provide the most optimal care possible for cancer patients. An active basic and clinical researcher, Dr. Catenacci is involved in bench-to-bedside translational research. He conducts basic investigations on normal and cancer cell signaling with the ultimate goal of developing new inhibitory drugs for the treatment of gastroesophageal cancer and other digestive malignancies. Additionally, Dr. Catenacci designs and executes clinical trials based on laboratory findings and discoveries.
Session Abstract – PMWC 2019 Silicon Valley
Session Synopsis: Precision oncology adoption into the clinical oncology workflow has been slow despite the technical and scientific advancements in molecular diagnostics and targeted therapeutics. Precision oncology incorporates in-depth genomic analysis of the patient’s tumor, interpretation of genomics results by the molecular tumor board (MTB), translation of findings into actionable therapeutic approaches, as well as navigation of the insurance and payor landscape in support of patients and providers. This session includes participants from various cancer centers that will share their learnings and the resulting added value to their institutions and medical communities, as well as the challenges they have to overcome when applying precision oncology through the MTB process.